138 related articles for article (PubMed ID: 38385428)
1. Design and Synthesis of Dual-Target Inhibitors Targeting Androgen Receptors and Glucocorticoid Receptors to Overcome Antiandrogen Resistance in Castration-Resistant Prostate Cancer.
Li C; Han X; Yan Q; Ji Y; Zhang R; Yuan D; Yang F; Wang J; Wu M; Zhou J
J Med Chem; 2024 Mar; 67(5):3419-3436. PubMed ID: 38385428
[TBL] [Abstract][Full Text] [Related]
2. Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer.
Wu M; Zhang R; Zhang Z; Zhang N; Li C; Xie Y; Xia H; Huang F; Zhang R; Liu M; Li X; Cen S; Zhou J
Elife; 2023 Jan; 12():. PubMed ID: 36656639
[TBL] [Abstract][Full Text] [Related]
3. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
[TBL] [Abstract][Full Text] [Related]
4. Abiraterone switches castration-resistant prostate cancer dependency from adrenal androgens towards androgen receptor variants and glucocorticoid receptor signalling.
Moll JM; Hofland J; Teubel WJ; de Ridder CMA; Taylor AE; Graeser R; Arlt W; Jenster GW; van Weerden WM
Prostate; 2022 Apr; 82(5):505-516. PubMed ID: 35037287
[TBL] [Abstract][Full Text] [Related]
5. Computationally guided discovery of novel non-steroidal AR-GR dual antagonists demonstrating potency against antiandrogen resistance.
Chai X; Hu XP; Wang XY; Wang HT; Pang JP; Zhou WF; Liao JN; Shan LH; Xu XH; Xu L; Xia HG; Hou TJ; Li D
Acta Pharmacol Sin; 2023 Jul; 44(7):1500-1518. PubMed ID: 36639570
[TBL] [Abstract][Full Text] [Related]
6. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
7. Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.
Lakshmana G; Baniahmad A
Int J Cancer; 2019 Apr; 144(8):1775-1779. PubMed ID: 30125354
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade.
Arora VK; Schenkein E; Murali R; Subudhi SK; Wongvipat J; Balbas MD; Shah N; Cai L; Efstathiou E; Logothetis C; Zheng D; Sawyers CL
Cell; 2013 Dec; 155(6):1309-22. PubMed ID: 24315100
[TBL] [Abstract][Full Text] [Related]
9. Identification of the gossypol derivatives as androgen receptor inhibitor.
Zhang R; Wu M; Cao T; Luo K; Huang F; Zhang R; Huang Z; Zhou J; Wang Y; Zhu S
Bioorg Med Chem Lett; 2022 Nov; 75():128952. PubMed ID: 36031018
[TBL] [Abstract][Full Text] [Related]
10. Is the glucocorticoid receptor a key player in prostate cancer?: A literature review.
Sakellakis M; Flores LJ
Medicine (Baltimore); 2022 Jul; 101(29):e29716. PubMed ID: 35866830
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.
Isikbay M; Otto K; Kregel S; Kach J; Cai Y; Vander Griend DJ; Conzen SD; Szmulewitz RZ
Horm Cancer; 2014 Apr; 5(2):72-89. PubMed ID: 24615402
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer.
Hoshi S; Meguro S; Imai H; Matsuoka Y; Yoshida Y; Onagi A; Tanji R; Honda-Takinami R; Matsuoka K; Koguchi T; Hata J; Sato Y; Akaihata H; Kataoka M; Ogawa S; Kojima Y
Cancer Sci; 2021 May; 112(5):1899-1910. PubMed ID: 33619826
[TBL] [Abstract][Full Text] [Related]
13. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
Martin SK; Kyprianou N
Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
[TBL] [Abstract][Full Text] [Related]
14. The expression of glucocorticoid receptor is negatively regulated by active androgen receptor signaling in prostate tumors.
Xie N; Cheng H; Lin D; Liu L; Yang O; Jia L; Fazli L; Gleave ME; Wang Y; Rennie P; Dong X
Int J Cancer; 2015 Feb; 136(4):E27-38. PubMed ID: 25138562
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
[TBL] [Abstract][Full Text] [Related]
16. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
[TBL] [Abstract][Full Text] [Related]
17. Discovery of a Novel Bifunctional Steroid Analog, YXG-158, as an Androgen Receptor Degrader and CYP17A1 Inhibitor for the Treatment of Enzalutamide-Resistant Prostate Cancer.
Wang A; Luo X; Meng X; Lu Z; Chen K; Yang Y
J Med Chem; 2023 Jul; 66(14):9972-9991. PubMed ID: 37458396
[TBL] [Abstract][Full Text] [Related]
18. Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer.
Moon SJ; Jeong BC; Kim HJ; Lim JE; Kim HJ; Kwon GY; Jackman JA; Kim JH
Theranostics; 2021; 11(2):958-973. PubMed ID: 33391515
[No Abstract] [Full Text] [Related]
19. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer.
Moses MA; Kim YS; Rivera-Marquez GM; Oshima N; Watson MJ; Beebe KE; Wells C; Lee S; Zuehlke AD; Shao H; Bingman WE; Kumar V; Malhotra SV; Weigel NL; Gestwicki JE; Trepel JB; Neckers LM
Cancer Res; 2018 Jul; 78(14):4022-4035. PubMed ID: 29764864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
